A new perspective on lowering CV risk from hypoglycaemia
- 11 October 2019
- journal article
- editorial
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 41 (2), 218-220
- https://doi.org/10.1093/eurheartj/ehz730
Abstract
This editorial refers to 'Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME (R) trial'(dagger), by D. Fitchett et al., on page 209.This publication has 15 references indexed in Scilit:
- Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME® trialEuropean Heart Journal, 2019
- Effects of Severe Hypoglycemia on Cardiovascular Outcomes and Death in the Veterans Affairs Diabetes TrialDiabetes Care, 2018
- The anti-diabetic drug dapagliflozin induces vasodilation via activation of PKG and Kv channelsLife Sciences, 2018
- The effect of empagliflozin on muscle sympathetic nerve activity in patients with type II diabetes mellitusJournal of the American Society of Hypertension, 2017
- Cardiac Autonomic Regulation and Repolarization During Acute Experimental Hypoglycemia in Type 2 DiabetesDiabetes, 2017
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesThe New England Journal of Medicine, 2015
- Ketone body metabolism and cardiovascular diseaseAmerican Journal of Physiology-Heart and Circulatory Physiology, 2013
- Increased QT Interval Dispersion Predicts 15-Year Cardiovascular Mortality in Type 2 Diabetic SubjectsDiabetes Care, 2012
- Epidemiologic Relationships Between A1C and All-Cause Mortality During a Median 3.4-Year Follow-up of Glycemic Treatment in the ACCORD TrialDiabetes Care, 2010
- Vascular disease and diabetes: is hypoglycaemia an aggravating factor?Diabetes/Metabolism Research and Reviews, 2008